Supernus SPN-820 Phase 2a data: rapid depressive symptom reduction with favorable tolerability

SUPERNUS PHARMACEUTICALS, INC.

HAM-D6 score improved -6.1 at 2 hours, -9.6 at Day 10; MADRS improved -16.6 at 4 hours, -22.9 at Day 10.
Suicidal ideation decreased 80% (from 12.5% to 2.6%) over 10 days.
SPN-820 well-tolerated; discontinuation rate 2.5% due to AEs; common AEs: headache, nausea, somnolence, dizziness.
Study enrolled 40 subjects; 38 completed 10-day treatment; open-label, adjunctive to baseline antidepressant.
Phase 2b double-blind placebo-controlled study topline results expected first-half 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.